At OncoVanta Therapeutics, we specialize in creating TCR-T cell therapies that precisely target mutant TP53 cancers. This innovative approach allows for a more focused treatment, minimizing damage to healthy cells and enhancing the body's immune response. Patients can experience a significant reduction in side effects commonly associated with traditional cancer therapies. By harnessing the power of immunotherapy, we aim to transform cancer treatment into a more effective and personalized journey. This means better outcomes and a brighter future for patients battling cancer.